|
Item
|
Detail
|
|---|---|
|
Primary Container
|
Amber type III glass bottle, 80mL nominal capacity
|
|
Closure
|
Child-resistant polypropylene screw cap with induction seal liner
|
|
Secondary Packaging
|
Printed cardboard carton with patient information leaflet
|
|
Accessories
|
Calibrated oral dosing syringe (1mL / 5mL graduations)
|
|
Carton Configuration
|
1 bottle per carton
|
Package:
Product Description
Product Overview
Artesunate Suspension 10mg/5mL is an oral liquid formulation containing artesunate, a semisynthetic derivative of artemisinin. Artemisinin is a naturally occurring compound isolated from the leaves of Artemisia annua L. (sweet wormwood), a plant with a long history of use in traditional herbal medicine. Each 5mL of the suspension provides 10mg of artesunate in a palatable, easy-to-administer liquid form.
Artesunate Suspension 10mg/5mL 80mL: What the Published Guidance Says
Artemisinin-based combination therapy is the WHO-recommended backbone of falciparum malaria treatment.
Artesunate Suspension 10mg/5mL 80mL sits in the Malaria & ACTs range. The notes below are the ones that most often change a specification, a label or a tender submission.
- The ACT combinations and their strengths are specified on the WHO Model List Section 6.5.3.1 of the 24th WHO Model List (2025) specifies the curative antimalarials, including artemether + lumefantrine tablet 20 mg + 120 mg and a dispersible tablet, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine as granules and tablets, dihydroartemisinin + piperaquine across four tablet strengths, and artesunate co-packaged with sulfadoxine + pyrimethamine. WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- ACT is the treatment of choice in all trimesters For uncomplicated P. falciparum malaria, MSF medical guidelines state the treatment of choice in all trimesters is an artemisinin-based combination therapy taken for three days. Co-formulated and co-blistered regimens are both described, including artemether/lumefantrine 20/120 mg and 80/480 mg, artesunate/amodiaquine, artesunate/mefloquine and dihydroartemisinin/piperaquine. MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- For severe malaria, parenteral artesunate is the drug of choice WHO guidance is artesunate 2.4 mg/kg by intravenous or intramuscular injection on admission, again at 12 and 24 hours, then once daily. Where artesunate is unavailable, intramuscular artemether 3.2 mg/kg on admission followed by 1.6 mg/kg daily is the alternative — artemether must never be given by the intravenous route. Parenteral treatment continues for at least 24 hours before switching to a full three-day oral ACT course. WHO — Malaria case management: operations manual
Each point above is reproduced because it has a practical consequence for Artesunate Suspension 10mg/5mL 80mL: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.
Supply & Specification Data for Artesunate Suspension 10mg/5mL 80mL
| Product Name | Artesunate Suspension |
| Specification | 10mg/5mL, 80mL bottle |
| Dosage Form | Oral Suspension |
| Active Ingredient | Artesunate |
| Route of Administration | Oral |
| Storage | Store below 25°C, protected from light and moisture. Do not freeze. Keep bottle tightly closed when not in use. |
| Therapeutic group | Malaria & ACTs — Malaria & ACTs |
| Manufacturer | Sinophare Bio-technology Co., Ltd. (GMP, China) |
| Documentation supplied | COA, HPLC/GC data, stability data, dossier package |
The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Artemether Suspension 15mg/5mL 60mL, Artemether-Lumefantrine Suspension 180/1080mg, Artesunate Suppositories 100mg, Artemether 80mg Injection, Artesunate 20mg + Pyronaridine 60mg Granules, Chloroquine Phosphate 500mg Tablets, Dihydroartemisinin 40mg + Piperaquine 320mg Tablets, Sulfadoxine/Pyrimethamine 175mg + Amodiaquine 75mg.
Testing, Monographs & Batch Documentation
Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.
Release testing for Artesunate Suspension 10mg/5mL 80mL follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.
Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.
The batch record for this product normally includes:
- Testing for dissolution or release profile (solid oral forms)
- Testing for uniformity of dosage units
- Testing for water content and pH where applicable
- Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
- Testing for microbial limits and preservative efficacy (multi-dose presentations)
- Testing for heavy metals and elemental impurities
COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.
Pack Configuration, Artwork & Shipping Documents
- Pack size: 80mL amber glass bottle with child-resistant cap, supplied with calibrated oral dosing syringe. Non-standard pack sizes can be quoted against your artwork.
- Storage: Store below 25°C, protected from light and moisture. Do not freeze. Keep bottle tightly closed when not in use..
- Shelf life: 24 months (unopened). Stability data for the marketed pack is included in the dossier.
- Labelling: we typeset the carton and leaflet in English, Arabic, French, Russian and Spanish and in any further language your market requires, carrying your own brand where the local rules allow.
- Export: commercial invoice, packing list, certificate of origin, GMP certificate, COA and the free-sale certificate issued by the country of manufacture whenever your customs or regulator asks for it.
Dossier, Authority Filings & Tender Documentation
The legal manufacturer named on every document for Artesunate Suspension 10mg/5mL 80mL is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.
- Artwork and mock-up approval pack, showing the carton, label and leaflet exactly as they will be printed for your market.
- Batch manufacturing and packaging records released for inspection on request during supplier audits.
- Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
- CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
- Site Master File and GMP certificate for the manufacturing workshops.
Artesunate Suspension 10mg/5mL 80mL is presented here against ACT regimens named in the WHO Model List of Essential Medicines. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.
Buyer Questions about Artesunate Suspension 10mg/5mL 80mL
What pack size is available for Artesunate Suspension 10mg/5mL 80mL?
Standard commercial packaging for this line is 80mL amber glass bottle with child-resistant cap, supplied with calibrated oral dosing syringe. Alternative pack sizes are produced to your specification and are supported by the corresponding stability data.
What documentation comes with a shipment of Artesunate Suspension 10mg/5mL 80mL?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 24 months.
Does the batch documentation for Artesunate Suspension 10mg/5mL 80mL support a registration filing?
The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.
Which ACT combinations appear on the WHO Model List?
The 24th List (2025) specifies artemether + lumefantrine, artesunate + amodiaquine, artesunate + mefloquine, artesunate + pyronaridine, dihydroartemisinin + piperaquine, artesunate co-packaged with sulfadoxine + pyrimethamine, and chloroquine restricted to P. vivax.
Do you supply dispersible paediatric ACTs?
Yes. We supply dispersible and dry-suspension presentations aligned to the strengths in the Model List, including artemether + lumefantrine 20/120 mg dispersible tablets and paediatric suspensions.
Other Malaria & ACTs Products in This Range
- Artemether Suspension 15mg/5mL 60mL — 15mg/5mL
- Artemether-Lumefantrine Suspension 180/1080mg — 1080mg
- Artesunate Suppositories 100mg — 100mg
- Artemether 80mg Injection — 80mg
- Artesunate 20mg + Pyronaridine 60mg Granules — 20mg
- Chloroquine Phosphate 500mg Tablets — 500mg
Browse the full Malaria & ACTs range; all Suspensions; the complete product catalogue.
Request a Quotation for Artesunate Suspension 10mg/5mL 80mL
Tell us the monograph, pack size and quantity required for Artesunate Suspension 10mg/5mL 80mL 10mg/5mL, together with the destination market, and the quotation will state lead time and the documents that ship with the batch. Samples for registration can be added to the same order.
Sources & Regulatory Notes
- WHO Model List of Essential Medicines, 24th List (2025) — report of the 25th WHO Expert Committee (TRS 1064)
- MSF Medical Guidelines — Malaria (Chapter 4.3, Parasitic infections)
- WHO — Malaria case management: operations manual
Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.
